NCT03277729
- Conditions
- Chronic Disease, Disease Attributes, Hematologic Diseases, +43 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Clinical trial condition
Refractory Diffuse Large B-Cell Lymphoma
Explore clinical trials studying Refractory Diffuse Large B-Cell Lymphoma. Study availability and eligibility vary by location and protocol.
66 public trials
20 recruiting studies
Refractory Diffuse Large B-Cell Lymphoma trial results
NCT03321643
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +14 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- UC San Diego Moores Cancer Center La Jolla, California, United States
- University of California Davis Comprehensive Cancer Center Sacramento, California, United States
- Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
Active, Not Recruiting
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT01955499
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +21 more
- Locations
-
- University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
- University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
Active, Not Recruiting
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
NCT03038672
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +53 more
- Locations
-
- Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Moffitt Cancer Center-International Plaza Tampa, Florida, United States
Active, Not Recruiting
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
- Locations
-
- University of California San Diego Moores Cancer Center La Jolla, California, United States
- Redlands Community Hospital Redlands, California, United States
- The Oncology Institute of Hope and Innovation Whittier, California, United States
- Baptist MD Anderson Cancer Center Jacksonville, Florida, United States
Active, Not Recruiting
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
NCT03479268
- Conditions
- B-Cell Prolymphocytic Leukemia, Chronic Disease, Disease Attributes, +40 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
- Roswell Park Comprehensive Cancer Center Buffalo, New York, United States
Active, Not Recruiting
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma
NCT02051257
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +14 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
Active, Not Recruiting
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
NCT05359211
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +17 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Active, Not Recruiting
Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL
NCT07393204
- Conditions
- Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
- Locations
-
- IRCCS Ospedale San Raffaele Milan, Italy
Active, Not Recruiting
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
NCT01959698
- Conditions
- CD20 Positive, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
- Locations
-
- Roswell Park Cancer Institute Buffalo, New York, United States